← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
101	101 Ginkgo Bioworks DNA $692M	–	–	–	–
102	102 Design Therapeutics DSGN $645M	–	–	–	–
103	103 Precision BioSciences DTIL $159M	–	–	–	–
104	104 Editas Medicine EDIT $361M	–	–	–	–
105	105 enGene Therapeutics ENGN $112M	–	–	–	–
106	106 Estrella Immunopharma ESLA $18.7M	–	–	–	–
107	107 FibroBiologics FBLG $6.88M	–	–	–	–
108	108 4D Molecular Therapeutics FDMT $671M	–	–	–	–
109	109 Fulgent Genetics FLGT $545M	–	–	–	–
110	FRLN 110 DELISTED Freeline Therapeutics Holdings plc American Depositary Shares FRLN	–	–	–	–
111	111 DELISTED Generation Bio GBIO	–	–	–	–
112	112 CytoMed Therapeutics GDTC $10.5M	–	–	–	–
113	113 Guardant Health GH $21.3B	–	–	–	–
114	GMDA 114 DELISTED Gamida Cell Ltd. Ordinary Shares GMDA	–	–	–	–
115	115 Corgi Genomics & Precision Medicine ETF GNMX $1.6M	–	–	–	–
116	116 Global X Genomics & Biotechnology ETF GNOM $95.5M	–	–	–	–
117	117 Genprex GNPX $1.73M	–	–	–	–
118	118 Genenta Science GNTA $32.5M	–	–	–	–
119	119 GRAIL Inc GRAL $5.26B	–	–	–	–
120	GRCL 120 DELISTED Gracell Biotechnologies Inc. American Depositary Shares GRCL	–	–	–	–
121	GRML 121 Greenland Mines Ltd GRML $80.1M	–	–	–	–
122	GTH 122 DELISTED Genetron Holdings Limited ADS GTH	–	–	–	–
123	123 Fractyl Health GUTS $20.6M	–	–	–	–
124	124 Franklin Genomic Advancements ETF HELX $28.8M	–	–	–	–
125	125 iShares Genomics Immunology and Healthcare ETF IDNA $306M	–	–	–	–